Novacap acquires interest in Spectrum Health Care
Novacap acquires interest in Spectrum Health Care TORONTO, July 15, 2019 /CNW Telbec/ – Novacap, a leading Canadian private equity firm, today announced it is acquiring a majority interest in Spectrum Health Care, a top provider of innovative home health care services in Ontario, investing alongside Spectrum’s existing management team. Spectrum offers a range of client-centred … Continue reading Novacap acquires interest in Spectrum Health Care
WHAT REALLY WORKS TO PULVERIZE THOSE DIMPLED THIGHS?
WHAT REALLY WORKS TO PULVERIZE THOSE DIMPLED THIGHS? www.gfacemd.com “Cottage cheese,” “funky gravy.” “hail damage” – whatever you want to call it – cellulite is never something we want to see on our bodies. That lumpy, dimple-looking flesh on our thighs, buttocks, abdomen, and hips is dreaded by women and men alike. Cellulite is caused … Continue reading WHAT REALLY WORKS TO PULVERIZE THOSE DIMPLED THIGHS?
Proposed Settlement of Canadian AMS Women’s Pelvic Mesh Litigation
Proposed Settlement of Canadian AMS Women’s Pelvic Mesh Litigation TORONTO, July 13, 2019 /CNW/ – Siskinds LLP, Rochon Genova LLP, Siskinds, Desmeules sencrl and Merchant Law Group announced today a Canada-wide settlement reached in two class actions related to certain mesh devices for treatment of Pelvic Organ Prolapse (“POP”) and Stress Urinary Incontinence (“SUI”) manufactured … Continue reading Proposed Settlement of Canadian AMS Women’s Pelvic Mesh Litigation
Using the Common Cold Virus to Treat Bladder Cancer
Using the Common Cold Virus to Treat Bladder Cancer Exciting New Advances in Oncolytic Virotherapy By Cancer Researcher Joshua Mansour, M.D. A runny nose, fever, and scratchy throat can be early signs of a cold. While it isn’t currently “cold season” which typically occurs in the fall and winter, a common viral cause of the … Continue reading Using the Common Cold Virus to Treat Bladder Cancer
ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports
ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer’s disease TORONTO and CAMBRIDGE, MA, July 9, 2019 /CNW/ – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a … Continue reading ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports
